R&D channel feed – Endpoints News

R&D channel feed

BioNTech says no to Phase 3 with Genmab’s bispecific antibody

9 months ago

Bristol Myers returns TIGIT bispecific to Agenus, frees itself from $1B+ milestones

9 months ago

Advisory committee votes in favor of Zevra Therapeutics' rare genetic disease drug

9 months ago

Massachusetts' plan for $1B in life science investment stalls in state legislature

9 months ago

Iron chelator therapy unexpectedly worsened Alzheimer’s disease in clinical study

9 months ago

Galapagos pauses blood cancer CAR-T therapy trial due to one Parkinsonism event

9 months ago

Agios' late-stage Pyrukynd trial in kids with rare blood disorder misses primary endpoint

9 months ago

Vertex says about 20 patients have started sickle cell therapy, cuts two rare disease programs

9 months ago

Arbutus reduces headcount after axing HBV combo trial that features Imfinzi

9 months ago

Updated: Jim Wilson to step down from gene therapy post at UPenn, will form two new companies

9 months ago

It took more than two decades for MDMA to reach the FDA. In two months, its prospects cracked. What happens next?

9 months ago

Updated: Eli Lilly’s tirzepatide reduces risk of heart failure outcomes in Phase 3 study

9 months ago

Sage changes main endpoint in Huntington's study months ahead of readout

9 months ago

ALX Oncology continues its CD47 quest, revealing Phase 2 gastric cancer data

9 months ago

Takeda defends Alzheimer's pact, TYK2 potential as restructuring is in 'full swing'

9 months ago

FDA questions Zevra’s resubmitted data for rare disease drug ahead of adcomm

9 months ago

Updated: Eisai says Alzheimer's drug keeps working after three years. But weaknesses in study raise questions

9 months ago

MacroGenics stops further dosing in Phase 2 prostate cancer drug trial

9 months ago

Takeda takes $140M hit on Phase 3 epilepsy flop, previews late-stage trials for pipeline prospects

9 months ago

Umoja to dose first patient with in vivo CAR-T by end of this year

9 months ago

Exclusive: Myeloid Therapeutics moves second in vivo cell therapy into trials, targeting liver cancer

9 months ago

FibroGen to shrink US workforce by 75% following more late-stage fails

9 months ago

Incyte drops four early-stage programs from its pipeline as part of strategic review

9 months ago

Imunon shares up over 150% as ovarian cancer treatment extends survival in Phase 2

9 months ago

First page Previous page 31 32 333435 36 37 Next page Last page